131I effective half-life (Teff) for patients with thyroid cancer

Health Physics

Volumn 91, Issue 2, 2006, Pages 119-122

  Willegaignon, J ^a   Malvestiti, Luiz F ^b   Guimarães, Maria I C ^c   Sapienza, Marcelo T ^b,c   Endo, Irene S ^b   Neto, Guilherme C ^b   Marone, Marília ^b   Sordi, Gian Maria A A ^a  

^a INSTITUTO DE PESQUISAS ENERGÉTICAS E NUCLEARES   (Brazil)

^b HOSPITAL SAMARITANO   (Brazil)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

131I; Cancer; Radiation protection; Thyroid

Indexed keywords

IODINE 131; RADIOACTIVE IODINE; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ARTICLE; CANCER PATIENT; CLINICAL PROTOCOL; CLINICAL TRIAL; DRUG HALF LIFE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT CARE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RADIATION PROTECTION; THYROID CANCER; ADOLESCENT; BODY BURDEN; CHEMISTRY; HALF LIFE TIME; METABOLIC CLEARANCE RATE; METABOLISM; METHODOLOGY; MIDDLE AGED; RELATIVE BIOLOGIC EFFECTIVENESS; RETROSPECTIVE STUDY; THYROID TUMOR; WHOLE BODY COUNTING;

ERAGROSTIS TEF;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BODY BURDEN; FEMALE; HALF-LIFE; HUMANS; IODINE RADIOISOTOPES; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; RADIOPHARMACEUTICALS; RELATIVE BIOLOGICAL EFFECTIVENESS; RETROSPECTIVE STUDIES; THYROID NEOPLASMS; WHOLE-BODY COUNTING;

EID: 33746144790     PISSN: 00179078     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.HP.0000202232.98823.87     Document Type: Article

References (11)

1. Benua RS, Cicale NR, Sonenberg M, Rawson RW. The relation of radioiodine dosimetry to results and complications in the treatment of metastatic thyroid cancer. AJR 87:171-182; 1962.
2. Driver I, Packer S. Radioactive waste discharge quantities for patients undergoing radioactive iodine therapy for thyroid carcinoma. Nucl Med Comm 22:1129-1132; 2001.
3. Harbert JC, Eckelman WC, Neumann RD. Nuclear medicine: diagnosis and therapy. New York: Thilme Medical Publisher Incorporation; 1996.
4. International Commission on Radiological Protection. Release of patients after therapy with unsealed radionuclides. Oxford: Pergamon Press; ICRP Publication 94; 2004.
5. Keating F, Haines S, Power M, Williams M. The radioiodine-accumulating function of the human thyroid gland as a diagnostic test in clinical medicine. J Clin Endocrinol Metabol 10:1425-1464; 1950.
6. National Council on Radiation Protection and Measurements. Precautions in the management of patients who have received therapeutic amounts of radionuclides. Bethesda: NCRP; Report No. 37; 1970.
7. Nicolau W, Medeiros-Neto G. Temas Atuais em Tireoidologia. São Paulo: Medeiros & Nicolau; 1977 (in Portuguese).
8. 131I in thyroid cancer patients. Health Phys 81:325-329; 2001.
9. Saenger EL, Kereiakes JG, Soddi VJ, David R. Radiotherapeutic agents: properties, dosimetry, and radiobiologic considerations. Seminars Nucl Med IX:72-84; 1979.
10. United Nations Scientific Committee on the Effects of Atomic Radiation. Sources and effects of ionizing radiation. 2000 report to the general assembly with annexes. Vienna: United Nations; 2001.
11. U.S. Nuclear Regulatory Commission. Release of patients administered radioactive materials. Washington, DC: U.S. Government Printing Office; Regulatory Guide 8.39; 1997.